FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Srinivasan Venkatesh					2. Issuer Name and Ticker or Trading Symbol SUTRO BIOPHARMA, INC. [STRO]									tionship of R all applicabl Director	•			to Issuer 10% Owner	
(Last) C/O SUTRO	(First)	,	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/01/2023								X	Officer (give title below)  Chief Tech Op		ı Op (	Other (specify below)  Officer		
111 OYSTER POINT BLVD.					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person						
(Street) SOUTH SAN FRANCISCO	CA	9	4080										X		,	•	ng Person Ine Reportin	g Person	
(City)	(State	) (2	Zip)																
		Т	able I - Non	-Deriv	vative S	Securitie	es Acq	juired, D	ispo	osed of	f, or B	enefic	ially Ow	ned					
1. Title of Security (Instr. 3)  2. Trans Date (Month/				Execut /Day/Year) if any		ned n Date, ay/Year)	Transaction Dispose Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 ar			5. Amount Securities Beneficially Following I	y Owned Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount (A)		A) or D)	Price	Transaction (Instr. 3 and				(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, ity (Instr. or Exercise (Month/Day/Year) if any			Cod	insaction de (Instr.	5. Numb Derivativ Securitie Acquired Dispose (D) (Instrand 5)	ve es d (A) or d of	Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction	i i illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Cod	de V	(A)	(D)	Date Exercisabl		xpiration ate	Title		Amount or Number of Shares		(Instr. 4)	on(s)			
Stock Option (right to buy Common Stock)	\$4.58	05/01/2023			A	7,500		(1)	05	5/01/2033	Com		7,500	\$0.00	7,500		D		
Restricted Stock Unit (RSU)	(2)	05/01/2023		1	A	10,000		(3)	05	5/01/2027	Com	mon	10,000	\$0.00	10,000	0	D		

## **Explanation of Responses:**

- 1. The option vests as to 2.0833% of the total shares monthly, beginning on June 1, 2023, with 100% of the total shares vested and exercisable on May 1, 2027, subject to the reporting person's provision of service to the issuer on
- 2. Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
- 3. The RSUs vest as to 1/4th of the total shares annually beginning on May 1, 2024, subject to continued service through each vesting date.

## Remarks:

/s/ Edward C. Albini as attorneyin-fact for Venkatesh Srinivasan

\*\* Signature of Reporting Person Date

05/02/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.